Bill Commons

NY A 500

in committee

Establishes a generic drug research and development laboratory and production facility and the empire state biosimilar insulin initiative

New York · 2025-2026 Regular Session · lower

Quick answers

Did NY A 500 pass?

Not yet. NY A 500 is in committee as of 2026-01-07 and has not come to a final vote. Latest recorded action (2026-01-07): REFERRED TO HEALTH

What is NY A 500 about?

Establishes a generic drug research and development laboratory and production facility to manufacture generic prescription drugs in the state and the empire state biosimilar insulin initiative, which will develop generic forms of the three most widely used forms of insulin.

Who sponsors NY A 500?

Phil Steck is the primary sponsor of NY A 500.

Description

Establishes a generic drug research and development laboratory and production facility to manufacture generic prescription drugs in the state and the empire state biosimilar insulin initiative, which will develop generic forms of the three most widely used forms of insulin.

Introduced
Latest action
2026-01-07 — REFERRED TO HEALTH
Bill type
bill
Last updated

Sponsors

  • Phil Steckprimary

Committees

Not provided by source.

Action timeline

  1. 2025-01-08

    REFERRED TO HEALTH

    referral-committee

  2. 2026-01-07

    REFERRED TO HEALTH

    referral-committee

Versions

Documents

Votes

Not provided by source.

Related bills

  • Prior session: A 9535not in this corpus

Official source

Attribution

Data from openstates_bulk_csv, retrieved 2026-07-24T05:28:30.722574Z

Inspect retained evidence for changes recorded after evidence tracking began:

Session-wide evidence can include changes to other bills:

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NY&identifier=A 500. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.

See the methodology page for data sources and limitations.